Corporate Overview

DRAXIS Health Inc., through its wholly owned operating subsidiary, DRAXIS Specialty Pharmaceuticals Inc. (DSPI), provides products in three categories: sterile products, non-sterile products and radiopharmaceuticals.

Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and sterile creams.

Non-sterile products are produced as solid oral dosage forms (tablets and capsules) and as semi-solid dosage forms (ointments and creams).

Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications.

Pharmaceutical contract manufacturing services are provided through the DRAXIS Pharma division of DSPI and radiopharmaceuticals are developed, produced, and sold through the DRAXIMAGE division of DSPI.

Consolidated operations are located in our 247,000 square foot facility near Montreal, Canada that is fully qualified by pharmaceutical regulators in the United States, Canada, Europe and elsewhere. DRAXIS employs approximately 500 staff in its Montreal facility.

The common shares of DRAXIS Health Inc. are listed on the Toronto Stock Exchange (ticker symbol DAX) and on the NASDAQ (ticker symbol DRAX).